Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry.

Autor:	Abd ElHafeez S; ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.; Epidemiology Department, High Institute of Public Health, Alexandria University, Alexandria, Egypt., Kramer A; ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.; Amsterdam Public Health, Quality of Care and Ageing & Later Life, Amsterdam, The Netherlands., Arici M; Department of Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Arnol M; Department of Nephrology, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia., Åsberg A; The Norwegian Renal Registry, Department of Transplantation Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway., Bell S; Scottish Renal Registry, Meridian Court, Glasgow, UK.; Division of Population Health and Genomics, University of Dundee, Dundee, UK., Belliere J; Department of Nephrology and Organ Transplantation, Referral Centre for Rare Kidney Diseases, University Hospital of Toulouse, Toulouse, France., Corte CD; Department of Nephrology, Hospital Universitario Central de Asturias, Oviedo University, Oviedo, Spain., Fresnedo GF; Hospital Universitario Marques de Valdecilla, Servicio de Nefrología, Cantabria, Spain., Hemmelder M; Division of Nephrology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.; CARIM School for Cardiovascular Diseases, University of Maastricht, Maastricht, The Netherlands., Heylen L; Dutch-speaking Belgian Renal Registry (NBVN), Sint-Niklaas, Belgium.; Dienst Nefrologie, Ziekenhuis Oost-Limburg, Genk, Belgium.; University Hasselt, Hasselt, Belgium., Hommel K; Nephrology Department, Holbaek Hospital, Holbaek, Denmark., Kerschbaum J; Austrian Dialysis and Transplant Registry, Department of Internal Medicine IV - Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria., Naumović R; Medical School, University of Belgrade, Serbia., Nitsch D; London School of Hygiene and Tropical Medicine, London, UK.; UK Renal Registry, Bristol, UK., Santamaria R; Andalusian Autonomous Transplant Coordination Information System, Seville, Spain.; Nephrology Service, Reina Sofia University Hospital, Cordoba, Spain., Finne P; Helsinki University Central Hospital, Division of Nephrology, Helsinki, Finland., Palsson R; Division of Nephrology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland., Pippias M; University of Bristol, Department of Health Care Evaluation, Population Health Sciences, Bristol, UK.; Bright Renal Unit, North Bristol NHS Trust, Bristol, UK., Resic H; Renal Registry of Society of Nephrology, Dialysis and Transplantation of Bosnia and Herzegovina, Clinic for Hemodialysis Sarajevo, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina., Rosenberg M; Competence Centre for Rare Diseases, Tartu University Hospital, Tartu, Estonia., de Pablos CS; Murcia Renal Registry, Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., Segelmark M; Division of Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden.; Department of Endocrinology, Nephrology and Rheumatology, Skane University Hospital, Lund, Sweden., Sørensen SS; Department of Nephrology Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Soler MJ; Department of Nephrology, Vall d'Hebron University Hospital, Barcelona, Spain., Vidal E; Department of Medicine (DAME), University of Udine, Udine, Italy.; Pediatric Nephrology Unit, University-Hospital of Padova, Padova, Italy., Jager KJ; ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.; Amsterdam Public Health, Quality of Care and Ageing & Later Life, Amsterdam, The Netherlands., Ortiz A; Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.; Department of Medicine, Universidad Autonoma de Madrid, Madrid, Spain., Stel VS; ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.; Amsterdam Public Health, Quality of Care and Ageing & Later Life, Amsterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2024 Aug 30; Vol. 39 (9), pp. 1449-1460.
DOI:	10.1093/ndt/gfae034
Abstrakt:	Background: Primary glomerular disease (PGD) is a major cause of end-stage kidney disease (ESKD) leading to kidney replacement therapy (KRT). We aimed to describe incidence (trends) in individuals starting KRT for ESKD due to PGD and to examine their survival and causes of death. Methods: We used data from the European Renal Association (ERA) Registry on 69 854 patients who started KRT for ESKD due to PGD between 2000 and 2019. ERA primary renal disease codes were used to define six PGD subgroups. We examined age and sex standardized incidence, trend of the incidence and survival. Results: The standardized incidence of KRT for ESKD due to PGD was 16.6 per million population (pmp), ranging from 8.6 pmp in Serbia to 20.0 pmp in France. Immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) had the highest incidences, of 4.6 pmp and 2.6 pmp, respectively. Histologically non-examined PGDs represented over 50% of cases in Serbia, Bosnia and Herzegovina, and Romania and were also common in Greece, Estonia, Belgium and Sweden. The incidence declined from 18.6 pmp in 2000 to 14.5 pmp in 2013, after which it stabilized. All PGD subgroups had 5-year survival probabilities above 50%, with crescentic glomerulonephritis having the highest risk of death [adjusted hazard ratio 1.8 (95% confidence interval 1.6-1.9)] compared with IgAN. Cardiovascular disease was the most common cause of death (33.9%). Conclusion: The incidence of KRT for ESKD due to PGD showed large differences between countries and was highest and increasing for IgAN and FSGS. Lack of kidney biopsy facilities in some countries may have affected accurate assignment of the cause of ESKD. The recognition of the incidence and outcomes of KRT among different PGD subgroups may contribute to a more individualized patient care approach. (© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu